For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
...space, Teva has found synergies between generics and OTC medicines via its one-year-old partnership with Procter & Gamble Co.... ...Pink:MBLTY), Melbourne, Australia MultiGene Vascular Systems Ltd. , Haifa, Israel NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Procter & Gamble Co....
...what contract structure will work best. One of the earliest began in January 2008, when Procter & Gamble Co.... ...taken Actonel for nine months, 15 had fractures that met the criteria for reimbursement from P&G... ...in December 2010 for reasons unrelated to the program itself. These included the acquisition of P&G's...
...to exercise its option to negotiate for OTC rights to Somaxon's insomnia drug Silenor doxepin. P&G... ...negotiation under a 2010 U.S. co-promotion deal. Somaxon ended the deal last year, but extended P&G's... ...$16.2 million in 2011 net sales for Silenor. Somaxon Pharmaceuticals Inc. (NASDAQ:SOMX), San Diego, Calif. Procter & Gamble Co....
...Phase II or higher. Commercial deals also expanded the company's footprint. Last year, Teva and Procter & Gamble Co.... ...BSE:NATCOPHAR), Hyderabad, India Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Procter & Gamble Co....
For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
...space, Teva has found synergies between generics and OTC medicines via its one-year-old partnership with Procter & Gamble Co.... ...Pink:MBLTY), Melbourne, Australia MultiGene Vascular Systems Ltd. , Haifa, Israel NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Procter & Gamble Co....
...what contract structure will work best. One of the earliest began in January 2008, when Procter & Gamble Co.... ...taken Actonel for nine months, 15 had fractures that met the criteria for reimbursement from P&G... ...in December 2010 for reasons unrelated to the program itself. These included the acquisition of P&G's...
...to exercise its option to negotiate for OTC rights to Somaxon's insomnia drug Silenor doxepin. P&G... ...negotiation under a 2010 U.S. co-promotion deal. Somaxon ended the deal last year, but extended P&G's... ...$16.2 million in 2011 net sales for Silenor. Somaxon Pharmaceuticals Inc. (NASDAQ:SOMX), San Diego, Calif. Procter & Gamble Co....
...Phase II or higher. Commercial deals also expanded the company's footprint. Last year, Teva and Procter & Gamble Co.... ...BSE:NATCOPHAR), Hyderabad, India Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Procter & Gamble Co....